Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PhosphoLean · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PhosphoLean | DRUG | - |
PhosphoLean is an investigational small molecule being developed for weight loss. It is in Phase 1 clinical development, with one completed trial that enrolled 60 participants. The drug is intended to address metabolic conditions related to weight management, though it is not yet approved and remains in early-stage clinical testing.
PhosphoLean is being developed by The Cooper Companies, Inc., a company traded on the New York Stock Exchange under the ticker COO. The company is advancing the drug through early clinical development for weight loss, with a completed Phase 1 trial as part of its investigational program.
PhosphoLean is in Phase 1 clinical development. The drug has completed one Phase 1 trial, which was an uncontrolled study with 60 participants. It is still investigational and has not been approved by regulatory authorities, as it remains in the early stages of clinical testing for weight loss.
PhosphoLean has one completed clinical trial, identified as NCT00153790, titled "LEAN Project: Weight Loss and Appetite Suppression." This Phase 1 study enrolled 60 participants and was an uncontrolled trial. The trial has been completed, and there are no active trials currently listed for the drug.
PhosphoLean is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for weight loss. The drug has completed one early-stage trial, but it has not yet undergone the later-phase studies required for regulatory approval, so it remains unapproved and in clinical testing.